Form 4: Dyne Therapeutics Director Dirk Kersten Sells Shares in Multiple Transactions

Dyne Therapeutics director Dirk Kersten sold a total of 110,933 shares of common stock in multiple transactions over two days, December 2nd and 3rd, 2024.

Summary

• Dirk Kersten, a director at Dyne Therapeutics, sold a total of 110,933 shares of common stock.
• The sales occurred over two days: December 2nd and December 3rd, 2024.
• On December 2nd, 79,973 shares were sold at a weighted average price of $29.66, with individual transactions ranging from $29.26 to $30.25.
• Also on December 2nd, 1,228 shares were sold at a weighted average price of $30.37, with individual transactions ranging from $30.26 to $30.46.
• On December 3rd, 29,732 shares were sold at a weighted average price of $29.05, with individual transactions ranging from $29.00 to $29.25.
• Following these transactions, Kersten indirectly beneficially owns 5,675,502 shares through ForDyne B.V. and 62,301 shares directly through FCF IV.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of stock sales by a director. It doesn't inherently indicate positive or negative sentiment, but the market's reaction could vary.

Risks

• The sale of a significant number of shares by a director could be perceived negatively by the market, potentially impacting the stock price.

Industry Context

This is a standard SEC Form 4 filing, which is common when company insiders trade shares. It provides transparency into the transactions of company directors and officers.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The volume of shares sold by Dirk Kersten is not unusual for a director of a company, but the market reaction will depend on the overall sentiment towards Dyne Therapeutics.
• Comparable companies in the biotech sector also have directors and officers who regularly file Form 4s when they buy or sell shares.

Stakeholder Impact

• Shareholders may react to the news of a director selling shares, potentially impacting the stock price.
• The sales do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Dyne Therapeutics, Dirk Kersten, stock sale, insider trading, Form 4, share transaction, beneficial ownership